anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The invention provides antigen polypeptide, a polypeptide composition and a vaccine for preparing a porcine circovirus synthetic peptide vaccine. The antigen polypeptide is polypeptide shown in the sequence 1, sequence 2, sequence 3 or sequence 4. The synthetic peptide vaccine comprises polypeptide or a polypeptide composition. The provided porcine circovirus synthetic peptide vaccine is excellent in immune effect and doesn&#39;t cause problems of fever and redness existing in conventional vaccine. The vaccine can effectively overcome the problems including antigenic variation of porcine circovirus and absence of biological safety, is easy for massive synthesis, and has bright application prospects. The invention further provides a preparation method of polypeptide and a polypeptide vaccine and a pharmaceutical application thereof.
The invention discloses a homatropine hydrobromide in situ gel preparation for eye dripping and the preparation method thereof, which relates to an ion sensitive eye in situ gel preparation and the preparation method thereof. The eye in situ gel takes homatropine hydrobromide as the active ingredient, gellan gum as the gel matrix and preservative, isotonic regulator, pH regulator and ultra-pure water as the assistants for the preparation. The in situ gel preparation of the invention makes use of complex of gel matrix, gellan gum and Ca&lt;2+&gt;, Na&lt;+&gt;, K&lt;+&gt; and other metal ions in tear to form stable hydrogen bonds, so as to be in the gel state. The in situ gel preparation is in liquid state in vitro and is in gel state when the invention is dripped in eye. The preparation combines the advantages of eye drops and eye ointments or gels and at the same time avoids the shortcomings of the two. Furthermore, the usage is convenient, the drug loss is reduced and the local bioavailability is improved.
Nerve regeneration devices are provided with improved rates of axonal regeneration, and methods for their manufacture are also disclosed. The devices are formed from a biocompatible, absorbable polymer, known as poly-4hydroxybutyrate. Growth factors, drugs, or cells that improve nerve regeneration may be incorporated into the devices. The devices are administered by implantation preferably without the use of sutures. In one aspect, the device is in the form of a wrap that can be used easily to capture the severed nerve bundle ends during surgery, and formed into a conduit in situ. If desired, the edges of the wrap can be melted together to seal the conduit, and hold it in place A major advantage of the device is that it does not need to be removed after use since it is slowly degraded and cleared by the patient&#39;s body, yet remains functional in situ beyond the time required for nerve regeneration, and helps exclude scar tissue. The device also degrades in a cell-friendly manner, and does not release highly acidic or inflammatory metabolites. Furthermore, the device is flexible, strong, does not crush the regenerating nerve, is easy to handle, reduces surgical time by eliminating the need to harvest an autologous graft, and allows the surgeon to repair the nerve without a prolonged delay.
1436355 Preparation of particulate materials P SPEISER 4 Dec 1973 [4 Dec 1972] 56045/73 Heading C3R [Also in Division A5] Particles having a diameter less than 200 nanometres (referred to as &#34;nanocapsules&#34;) are made by forming a dispersion with substantially mutually insoluble aqueous and hydrophobic phases in which the particles of disperse phase are less than 200 nanometres in diameter and contain both a polymerizable monomer substantially insoluble in the continuous phase and an active material, and causing polymerization of the monomer without substantially decomposing the active material. The product is said to be composed of particles of various structures including a &#34;microcapsular&#34; structure and forms in which the active material is held within a molecular lattice of the polymer. It may be made by forming an aqueous phase in which the active material is dissolved or colloidally disposed, dispersing it in an immiscible non-aqueous phase, e.g. n-hexane, adding a water-insoluble monomer, e.g. acrylamide or N,N&lt;SP&gt;1&lt;/SP&gt;-methylene-bis-acrylamide and causing polymerization thereof, e.g. by irradiation. A suitable surface active agent may be added to the continuous phase to assist in dispersing the disperse phase the process being carried out using either an aqueous (as above) or non-aqueous disperse phase. In the latter case, suitable monomers for use are acrylic and methacrylic acids. The particles may subsequently be separated, e.g. by filtration, centrifugation or distillation of the liquid phases. Specific examples relate to the preparation of particles containing diphtheria or tetanus toxoid, human gamma globulin, urease and riboflavin-5&lt;SP&gt;1&lt;/SP&gt;-sodium phosphate.
Described herein are compositions that include an aqueous phase and 5 to 30%, by weight, of an oil phase, based on the total weight of the composition. The oil phase comprises the omega-3 fatty acid triglyceride eicosapentaenoic acid triglyceride, docosahexaenoic acid triglyceride, or mixtures thereof. The composition further comprises at least one amphoteric surfactant, at least one co-surfactant, and at least one co-solvent. The compositions comprise less than 0.03% by weight of sodium oleate, based on the total weight of the composition. Also described are methods for preparing such compositions as well as such compositions for use as a medicament, in particular for use in treating stroke, sepsis, Alzheimer&#39;s disease or cancer. Also featured are methods of treating these conditions by parenterally administering a composition to a patient in need and methods of providing parenteral nutrition to such patients by administering to them a composition as described herein.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to the creature of the preparation with analgetic effect. Invention proposes the preparation made as a capsule that comprises tramadol hydrochloride and the following accessory substances: microcrystalline cellulose, magnesium stearate and silicon dioxide taken in the definite ratio of components. Preparation exhibits low toxicity and doesn&#39;t cause disturbances in biochemical and hematological blood indices owing to qualitative and quantitative selection of components. EFFECT: valuable medicinal properties of preparation. 2 dwg, 6 tbl
PURPOSE:To assay an objective substance with high sensitivity, by containing either one of apoenzyme and the corresponding coenzyme in a microcapsule receiving lytic action by antigen/antibody reaction and containing the other one outside the microcapsule. CONSTITUTION:Apoenzyme and coenzyme are separately received inside and outside a microcapsule. For example, as the microcapsule, a red corpuscle is used and apoglucose oxidase is used as the substance included in the microcapsule an the absorbancy of the reaction solution is measured at a wavelength of 600nm. 10mul of the microcapsule having anti-T4 antibody preliminarily bonded to the surface thereof and 10mul of a solution containing a complement, coenzyme and glucose are mixed with 10mul of a solution containing T4 at known concn. to perform reaction for 20min. After 20min, 20mul of a solution containing peroxidase and 4-aminoantipyrine diethylaniline and 950mul of a 50mMKH2PO4 buffer solution are mixed with the reaction solution to perform reaction for 20min. By this method, absorbancy increases as T4 increases and a T4&lt;-&gt; calibration curve can be formed.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a patient monitoring and dosing system, in more detail, a method and instrument to increase the efficiency of medical manipulation.  &lt;P&gt;SOLUTION: The patient monitoring and dosing system used during a diagnosis, an operation or other medical manipulation and a related method are disclosed. The functionality of the system permits difficult work consuming much time to be minimized or transferred to a part of manipulation in which time is not especially important. The system can increase efficiency at a patient care facility by turning the configuration and design of the system as a whole into two separate units. A patient unit 10 receives an input signal from a patient monitoring connection and outputs the received signal to a manipulation unit. The manipulation unit 12 operates during medical manipulation and controls dosing to a patient.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
516,513. Food preparations; medicines; cocoa. WELLS, E. E., and ROWNTREE &amp; CO., Ltd. March 22, 1938, Nos. 8834 and 8835. Drawings to Specification. [Classes 49, 81 (i) and 129] . One of a combination of ingredients, which is to be converted into food or medicine by the addition of a hot liquid, is dispersed or enclosed in an insulating agent which prevents the insulated ingredient from being decomposed or allowed to react with another ingredient as a result of the heat of the liquid while the liquid is hottest. Water-soluble materials, such as sugar, gelatine or gum or water-soluble materials such as fats, waxes, varnish or gelatine made insoluble by treatment with formaldehyde may be used as insulating agents. An envelope of rice paper may be used as an insulating agent. The invention is applicable in connection with table jellies or meat cubes containing laevoascorbic acid, known as vitamin C. Thus vitamin C, mixed in dry-form with -sugar or starch or with a binding agent such as stearic acid, may be formed into tablets or coated with gelatine, gelatine sugar or other insulator, and the tablets inserted into jelly liquor after the latter has been poured into the moulds. A granulated mixture of vitamin C with small quantities of gum arabic, French chalk, and liquid paraffin for use in tablet form is described. Gelatine capsules containing vitamin C in solution may be used. Specification 490,001 is referred to. Provisional Specifications state that vitamin C insulated in gelatine may be added to cocoa powder, malted milk powder or dried milk powder.
PURPOSE:To readily obtain the subject liquid substance by mixing soybean milk with monosodium glutaminate, saccharides and amino acids in a specific proportion, adding Bacillus NATTO, absorbing the resultant mixed raw material on a cellular substrate, fermenting and extracting the formed stringy liquid substance. CONSTITUTION:Soybeans are washed with water, dipped in water, ground and filtered. One-5pts.wt. monosodium glutaminate, 2-8pts.wt. saccharides and 0.5-3.5 pts.wt. amino acids are added and mixed with 100pts.wt. resultant soybean milk and heated. Bacillus NATTO is then added thereto. The obtained mixed raw material is absorbed in a cellular substrate, such as sponge sheet, fermented and cooled to form a stringy liquid substance, which is then extracted by centrifugation, etc., to afford the aimed liquid substance suitable as a raw material for food, etc., resembling a stringy viscous substance on the surface of &#39;NATTO&#39; (fermented soybean) at a low cost.
A sugar free tooth &#34;n&#34; gum chewing gum (FIG 1, not shown) has been impregnated with an effective concentration of magnesium trisilicate which neutralises plaque and food acids, and acts as a tooth polish during the chewing action. A number of further components may be added to the sugar free chewing gum. For example, the addition of calcium pyrophosphate provides an effective agent against plaque and tartar; the addition of an anti-bacterial artificial sweetener, such as xylitol, improves the anti-plaque action and eliminates the sugar substrate that plaque bacteria feed on. Extra artificial sweeteners like sorbitol, improve flavour. Other additives may include cetylpyridinium chloride, which is an anti-bacterial and mouth ulcer treatment, breath fresheners and different flavours to enhance the appeal of the product. Each stick of chewing gum may be hygienically wrapped in its own foil and paper wrapping and these may in turn be sold in plastic wrapped multi packs.
PURPOSE: To obtain a gelatinous cosmetic providing hair with luster and gloss, having excellently hair setting power and preventing effect on split hair by blending a system comprising a hydrocarbon oil component with water and a lower alcohol with a specific silicone compound. CONSTITUTION: This gelatinous cosmetic comprises a hydrocarbon oil component, water, a lower alcohol and a polyether-modified silicone of the formula [A is methyl, phenyl, C3 H6 O-(C2 H4 O)a (C3 H6 O)b R&#39; (R&#39; is H, an acyl or an alkyl; (a) and (b) are each 5-50), at least one A among three As is a polyoxyalkylene; R is methyl or phenyl; (m) is 50-1,000; (n) is 1-40] as constitutuent components. The blending ratio is the lower alcohol/water = 2/1-1/20 (weight ratio). Isoparaffin, especially a 4-20C volatile isoparaffin is suitable as the hydrocarbon oil component. Ethanol is suitable as the lower alcohol. The gelatinous cosmetic is readily applied and has excellent stability with time.
The invention discloses a novel application of the extract of Rheum emodi Wall., and more specifically discloses an application of the extract of Rheum emodi Wall. in preparing anti-fibrosis drugs. According to results of animal experiments, the extract of Rheum emodi Wall. prepared by ethanol percolation and extraction and ethanol elution, especially 3,5,3&#39;,4&#39;-tetrahydroxystilbene-4&#39;-O-beta-D-glucopyranoside (PDG) in the extract, can inhibit the expression of transforming growth factor-beta 1 and the expression of TIMP-1 and promote the expression of Caspase-3 in fibrotic tissue, thereby reducing the generation and deposition of extracellular matrix (ECM) and substantially alleviating fibrosis of tissue. In the controlling of hepatic fibrosis, PDG can inhibit the activation and propagation of hepatic stellate cells (HSC) and induce the apoptosis of HSCs; as a whole, PDG has a substantial retroconversion effect on hepatic fibrosis of rats. Therefore, the extract of Rheum emodi Wall. or medical combinations containing the extract of Rheum emodi Wall. can be used for the preparation of anti-fibrosis drugs.
PURPOSE:A sustained release suppository gradually releasing a drug to digestive tubes and keeping medicinal effects for a long period, obtained by blending a high-melting suppository base with hydrogenated lecithin. CONSTITUTION:100pts.wt. high-melting suppository base having 40-45 deg.C melting point is blended with &gt;=5pts.wt. hydrogenated lecithin. Prolongation can be regulated by properly selecting the amount of the hydrogenated lecithin blended, can suppress rapid rise in drug concentration in blood after suppository administration and prevent side effects caused by drug. An anti-inflammatory analgesic is especially preferable as the suppository used.
The present invention discloses a compound with the general formula I, which is a beta-L-2&#39;-deoxidation-nucleoside derivative. Moreover, the present invention discloses a preparation method and the application field of the compound. Beta-L-2&#39;-deoxidation-uridine is used as main raw materials, and the raw materials are etherified, vulcanized, reduced and synthesized into the beta-L-2&#39;-deoxidation-nucleoside derivative under certain condition, wherein R1 represents H and C1-C6 alkyl groups; R2 represents H, CH3 and F; R3 represents H, monophosphate, diphosphate, triphosphate, phosphate derivatives, amino acid and C1-C6 alkyl groups. The compound can be used for treating diseases relevant to hepatitis B viruses, acquired immune deficiency syndrome viruses, etc. The compound overcomes the problem of easy relapse during discontinued medication of the existing medicine for treating hepatitis B and acquired immune deficiency syndrome. The compound of the present invention has the advantages of high activity for resisting HBV, small toxice effect and side effect and little resistance generation. The present invention has higher clinical value and application prospect.
PURPOSE:To provide an afterfoaming aerosol pack stock causing no foaming in its delivery, good in application feel, ready to remove by water and also giving warm feel, containing clay mineral(s). CONSTITUTION:The objective pack stock containing &gt;=0.1wt.% (pref. 0.1 to 3.0) wt.% of at least one kind of clay mineral selected from montmorillonite, bentonite, hectorite and caolinite, etc. As a foaming agent, 2 to 7wt.%, based on the whole amount of the final pack stock, of propane, 1-butane or CFC-11 is used, being put into a specific vessel separated from that for a propellent and subjected to agitation mixing to obtain the objective product. Afterfoaming means that, when the present pack stock is delivered under static atmospheric conditions at 20 deg.C from an aerosol can, no foaming can virtually observed with the naked eye and white foams are gradually developed in &gt;=30sec. When the present pack stock is applied on the skin, the vaporization of the foaming agent will become earlier due to the skin temperature, thus effecting gradual foaming.
The invention discloses a polypeptide closely connected to immunogen, and belongs to the field of anticancer vaccines. The invention specifically relates to an optimized polypeptide, used as an anticancer vaccine, closely connected to the immunogen, and the optimized polypeptide strengthens T cell immune response. An amino acid sequence is a brand-new sequence, the polypeptide is chemically synthesized; or a genetic recombination method is adopted, so that polynucleotide for coding the polypeptide can be expressed to obtain the polypeptide. The polypeptide closely connected to the immunogen is used for immunogen in an ovarian cancer tumor immune cell technology, and strengthening T cell immune response. The polypeptide closely connected to the immunogen has the beneficial effects that the sequence is the brand-new sequence, and the polypeptide can be used for the immunogen in the ovarian cancer tumor immune cell technology, can promote T cells, can promote CD8&lt;+&gt; immune response, can be specifically combined with MHC on the surfaces of the T cells effectively, and can inhibit growth of ovarian cancer tumors in a cancer-borne mice body. As a target molecule of cell therapy, the polypeptide closely connected to immunogen is applied to cell therapies such as CAR-T.
PROBLEM TO BE SOLVED: To obtain the subject improver having effect of reducing total cholesterol levels and neutral lipid levels in the plasma and effect of increase in the excretion of both cholesterol and bile acid into feces by including a decomposition product of royal jelly formed by the action of protease. SOLUTION: This lipid metabolism improver comprises a decomposition product of royal jelly formed by the action of protease. The decomposition product consists mainly of a peptide pref. &lt;=3,000 in molecular weight, being obtained by the following process: at least two kinds of protease preferably differing in site of action on a substrate are added either simultaneously or sequentially to a royal jelly suspension followed by holding the suspension at room temperature or higher to carry out an enzyme reaction; wherein the above two or more kinds of protease to be used are e.g. acidic protease, neutral protease, alkaline protease, each originated from microorganisms or plants, digestive enzymes derived from mammals such as pepsin and pancreatin. It is preferable that, when to be added to a drink or the like, the above decomposition product is at 0.5-3 wt.% on a dry basis.
The present invention belongs to technical field of medicine, and relates to the preparing of cleavable polyethylene glycol (PEG) lipid derivative and an application thereof in the liquid particle preparation. The general formula is as follows: CH3O(CH2CH2O)n-R-O-R&lt;1&gt;, wherein n=5-5000, the molecular weight of PEG is 300-30000, R represents one group selected from hemisuccinate group and carbomethoxy, and the liposoluble fragment represented by R&lt;1&gt; comprises one component selected from cholesterol, sitosterol, alpha-tocopherol. According to the invention, polyethylene glycol is connected with lipoid derivatives such as cholesterol, alpha-tocopherol, etc. through ester linkage. The cleavable PEG lipid derivative can be applied to the modification of liquid particle preparation. On one hand, the PEG lipid derivative has appropriate adhesive force of the surface of liquid particle preparation and guarantees enough holding time of PEG lipid derivative in blood. On the other hand, the PEG lipid derivative can gradually break away from the surface of preparation in the circulation process. The particle preparation which only comprises a few polyethylene glycol on the surface can combine and phagocytose the pathological cell. The medicine is delivered into the cell and therefore has the function of selectively killing the pathological cell.
NEW MATERIAL:The phospholipid A contg. choline having the following characteristics: colorless oily substance; molecular weight, 805 and 831 by FD-MS and SIMS; soluble in ether, methanol, etc., insoluble in acetone and water; positive to Dragendorff reagent, Dittmer-Lester reagent, etc.; negative to H2SO4, ninhydrin reagent, etc. USE:Carcinostatic agent. PROCESS:The embryo of a rainbow trout (salma gairdneri) of 12-14 days after fertilization is homogenized, and extracted successively with acetone, ether, and a chloroform-methanol mixture. The extracts are mixed to together, concentrated in vacuum, and developed by silica gel column chromatography. The active component existing in the chloroform-methanol fraction is purified to obtain the phospholipid A. The objective drug having excellent carcinostatic activity and low toxicity can be obtained by using the phospholipid A as an active component. Dose: 0.01-100mg/kg daily for oral administration and &lt;= about 10mg/kg daily for parenteral administration.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to traumatology and orthopaedics, and can be used for treating a medial meniscus injury without reaching an articular surface bordering on the joint cavity. Method involves a preliminary examination with MRI of the injured region of the joint, determination of a degenerative meniscus adjustment zone and introduction of a therapeutic composition stimulating the restoration of the damaged tissue in the area of injury. Therapeutic composition used is a platelet-derived mixture obtained from intrinsic blood, which, under ultrasonic control, is delivered into the degenerative meniscus adjustment zone by transcutaneous insertion of the needle into the meniscus thickness produced from the popliteal fossa. Therapeutic composition is administered until filling the whole volume of the damaged meniscus tissue. Therapeutic composition can also be introduced directly through the posterior surface of the joint into the meniscus and into the border zone of the capsule at a point closest to the posterior horn of the medial meniscus. Thrombocyte mixture can be administered in amount of 0.5 ml. When the needle is removed, 0.5 ml of a platelet mixture is added to the border zone of the joint capsule, and the platelet preparation is introduced with a puncture needle. Filling of the affected area with a drug is carried out from the centre of the area to its periphery.EFFECT: method provides efficiency and safety ensured by manipulations only in the area of joint damage and using patient&#39;s own blood.6 cl, 3 ex